Core Viewpoint - vTv Therapeutics Inc. is advancing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, and is actively participating in investor conferences to discuss its developments [1][2]. Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for diabetes and other chronic diseases [2]. - The clinical pipeline is led by cadisegliatin, which is currently in a US Phase 3 trial for type 1 diabetes [2]. Product Details - Cadisegliatin (TTP399) is a novel, liver-selective glucokinase activator being investigated as an oral adjunctive treatment for type 1 diabetes [3]. - In non-clinical studies, cadisegliatin has shown the ability to increase glucokinase activity independently from insulin, suggesting potential for improved glycemic control [3]. - The product has received Breakthrough Therapy designation from the U.S. FDA, indicating its potential significance in treatment [3].

Core Insights - vTv Therapeutics has expanded its license agreement with Newsoara Biopharma, granting Newsoara global rights to develop and commercialize the PDE4 inhibitor HPP737, which is aimed at treating inflammation-mediated diseases [1][3] - The agreement includes an upfront payment of $20 million, potential future development milestones of approximately $50 million, sales milestones of up to $65 million, and tiered royalties based on net sales [2][3] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for chronic diseases, particularly type 1 diabetes [8] - The company's lead product, cadisegliatin, is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA [6][8] Product Details - HPP737 is a selective phosphodiesterase type 4 (PDE4) inhibitor that has shown therapeutic activity in animal models of inflammation and has been well tolerated in phase 1 studies [3][4] - The drug aims to address unmet needs in inflammation-mediated diseases and may avoid gastrointestinal side effects commonly associated with other PDE4 inhibitors [4] Strategic Collaboration - The collaboration with Newsoara is seen as a strategic priority for vTv, enhancing its balance sheet and providing a significant source of potential value creation for shareholders [2][3] - Newsoara plans to leverage its development and commercialization capabilities to advance HPP737 and bring it to patients worldwide [3][9]

Company Overview - vTv Therapeutics (VTVT) is a biopharmaceutical company valued at $156 million, focusing on the discovery and development of orally administered small molecule drug candidates to address unmet medical needs [1] - The company is developing azeliragon TTP488 for Alzheimer's disease, currently in Phase 3 clinical trials, along with candidates for Type 1 and Type 2 diabetes, cancers, psoriasis, and COPD [1] Stock Performance - VTVT has experienced a significant surge of 182% over the past year, reaching a two-year high [4] - The stock recently traded at $41.35, with a 50-day moving average of $30.06, and has gained 51.55% in the last month [5] - Since the Trend Seeker issued a new "Buy" signal on December 8, the stock has increased by 35.86% [2] Technical Indicators - vTv Therapeutics scored a new two-year high of $41.49 on December 31 [3] - The company has a Weighted Alpha of +225.52 and a Relative Strength Index (RSI) of 77.02, indicating strong momentum [5] - Barchart gives vTv Therapeutics a 100% "Buy" opinion, with Wall Street leaning towards a "Strong Buy" rating and price targets reaching up to $47 [4][5]

Core Viewpoint - vTv Therapeutics has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade reflects an improvement in vTv Therapeutics' underlying business, suggesting that investors may respond positively by driving the stock price higher [4]. - For the fiscal year ending December 2025, vTv Therapeutics is expected to earn -$3.35 per share, with a 9.2% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6][8]. - The upgrade to Zacks Rank 2 places vTv Therapeutics in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - vTv Therapeutics Inc. has announced a Phase 2 clinical study for cadisegliatin, an oral adjunctive therapy to insulin for type 2 diabetes, in collaboration with M42's Insights Research Organization & Solutions [1][2] Group 1: Clinical Study Details - The Phase 2 study protocol has been submitted to the Department of Health Abu Dhabi and aims to evaluate the safety and efficacy of cadisegliatin over a 12-month period [1] - The trial will enroll approximately 300 patients with type 2 diabetes who are treated with insulin, randomized into three groups: two cadisegliatin dose groups (400 mg and 800 mg once daily) and a placebo control group [1] - The trial will take place in the UAE, Jordan, and Tunisia, with the first patient visit expected in Q1 2026 [1] Group 2: Company and Product Information - Cadisegliatin (TTP399) is a novel oral small molecule being investigated as a potential first-in-class oral adjunctive treatment for type 1 diabetes and has received Breakthrough Therapy designation from the FDA [4][6] - vTv Therapeutics is focused on developing oral, small molecule drug candidates for diabetes and other chronic diseases, with cadisegliatin leading its clinical pipeline [6] Group 3: Collaboration and Market Potential - The collaboration with M42 allows vTv to expand the geographic footprint for cadisegliatin, targeting populations with high prevalence of type 2 diabetes, particularly in the UAE [2][3] - IROS, as the funding partner for the study, aims to leverage its expertise in clinical research to potentially impact the lives of millions with type 2 diabetes [3][7]

Core Viewpoint - vTv Therapeutics (VTVT) has shown a significant price increase of 41.4% over the past four weeks, with a mean price target of $37 indicating a potential upside of 25.2% from the current price of $29.56 [1] Price Targets and Analyst Consensus - The average price target for VTVT ranges from a low of $35.00 to a high of $40.00, with a standard deviation of $2.65, suggesting a relatively tight clustering of estimates [2] - The lowest estimate indicates an 18.4% increase, while the highest suggests a 35.3% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about VTVT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 9.2% over the past month, with no negative revisions reported [12] - VTVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can often mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - vTv Therapeutics (VTVT) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Rising earnings estimates for vTv Therapeutics suggest an improvement in the company's underlying business, likely leading to an increase in stock price [5][10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - The upgrade of vTv Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, vTv Therapeutics is expected to earn -$3.35 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.2% over the past three months [8].

Financial Performance - The company has not generated any revenue from drug sales to date, relying primarily on milestone payments and research fees [100]. - Revenue for the nine months ended September 30, 2025, was $0, a decrease of $1.0 million compared to $1.0 million in 2024 [118]. - The net loss attributable to vTv Therapeutics Inc. for the three months ended September 30, 2025, was $8.7 million, compared to a net loss of $4.8 million in 2024 [111]. - Net loss attributable to vTv Therapeutics Inc. increased by $5.0 million, from $14.8 million in 2024 to $19.8 million in 2025 [117]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $7.0 million, an increase of $3.8 million or 117.7% compared to $3.2 million in 2024, driven by increased spending on cadisegliatin and other projects [113]. - General and administrative expenses increased by $0.4 million or 12.1% to $3.7 million for the three months ended September 30, 2025, compared to $3.3 million in 2024 [114]. - Total operating expenses for the three months ended September 30, 2025, were $10.7 million, an increase of $4.2 million compared to $6.5 million in 2024 [111]. - Research and development expenses increased by $4.6 million, or 49.8%, from $9.3 million in 2024 to $14.0 million in 2025, primarily due to increased indirect costs and spending on cadisegliatin [119]. - General and administrative expenses remained flat at $11.0 million for both periods, with a slight decrease of $0.0 million or 0.1% [120]. Cash Flow and Financing - As of September 30, 2025, the company had cash and cash equivalents of $98.5 million, with an accumulated deficit of $319.6 million [124]. - Net cash used in operating activities decreased by $4.5 million, from $20.5 million in 2024 to $16.0 million in 2025 [130]. - Net cash provided by financing activities increased to $77.8 million in 2025, compared to $52.6 million in 2024, driven by a private placement [132]. - The company plans to finance operations through cash reserves and future funding activities, including potential licensing and monetization of programs [134]. - The company has sold 179,400 shares under the TD Cowen ATM Offering for net proceeds of $2.5 million, leaving $47.5 million available to be sold [128]. Research and Development - The company expects to have top-line data from the CATT1 study in the second half of 2026, following a protocol amendment to shorten the study duration from 12 months to 6 months [96]. - The FDA granted Breakthrough Therapy designation for cadisegliatin in 2021, supporting its development as an adjunctive therapy to insulin for type 1 diabetes [95]. - The company initiated a food effect study in June 2025 to assess the impact of food on the pharmacokinetics of cadisegliatin, with data currently being analyzed [97]. - A Phase 2 trial in the Middle East for cadisegliatin in type 2 diabetes patients is expected to begin in the fourth quarter of 2025, involving 300 patients [98]. Financial Risks - The company has no material interest rate exposure, indicating a stable financial position regarding interest rates [144]. - Market risk exposure is limited to cash and cash equivalents with maturities of one year or less, focusing on capital preservation and liquidity needs [145]. - The investment strategy aims to maximize income from investments without assuming significant risk, maintaining cash with high credit quality institutions [145]. - There is no material foreign currency exposure, suggesting minimal risk from currency fluctuations [146].

Financial Performance - vTv Therapeutics reported a net loss of $8.7 million or $1.08 per basic share for Q3 2025, compared to a net loss of $4.8 million or $0.88 per basic share in Q3 2024[6]. - Total operating expenses for Q3 2025 were $10.7 million, compared to $6.5 million in Q3 2024[10]. - vTv Therapeutics' accumulated deficit reached $319.55 million as of September 30, 2025, compared to $299.72 million at the end of 2024[8]. Cash Position - The company's cash position increased to $98.5 million as of September 30, 2025, up from $36.7 million at the end of 2024[5]. - The total liabilities increased to $28.95 million as of September 30, 2025, from $23.97 million at the end of 2024[8]. Research and Development - Research and development expenses rose to $7.0 million in Q3 2025, compared to $3.2 million in Q3 2024, reflecting increased spending on cadisegliatin and other projects[6]. - vTv Therapeutics successfully completed an $80 million private placement in September 2025 to fund the ongoing CATT1 Phase 3 trial[5]. - The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025, with topline data expected in the second half of 2026[5]. - The company anticipates reporting topline results from the CATT1 trial in the second half of 2026[2]. Intellectual Property - The U.S. Patent and Trademark Office allowed claims for a new patent covering crystalline forms of cadisegliatin, with exclusivity expected until 2041[5].

Core Insights - vTv Therapeutics is advancing its cadisegliatin program, a potential first-in-class oral adjunctive therapy for type 1 diabetes, with topline Phase 3 CATT1 data expected in the second half of 2026 [1][2] - The company successfully completed an $80 million private placement to strengthen its balance sheet and support the ongoing Phase 3 trial [1][5] - A new U.S. patent covering crystalline salts and co-crystals of cadisegliatin has been issued, providing exclusivity until 2041 [1][5] Recent Company Highlights - The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025 [5] - The patent allowance for cadisegliatin's crystalline salt form was granted by the U.S. Patent and Trademark Office [5] - The cash position as of September 30, 2025, was $98.5 million, a significant increase from $36.7 million as of December 31, 2024 [5][7] Third Quarter 2025 Financial Results - Research and Development (R&D) expenses increased to $7.0 million in Q3 2025 from $3.2 million in Q3 2024, reflecting higher spending on cadisegliatin and other projects [5][9] - General and Administrative (G&A) expenses rose to $3.7 million in Q3 2025 from $3.3 million in Q3 2024, primarily due to payroll and legal expenses [5][9] - The net loss attributable to vTv shareholders for Q3 2025 was $8.7 million, or $1.08 per basic share, compared to a net loss of $4.8 million, or $0.88 per basic share, in the same period last year [5][10]